47 completed, 10 unknown, 9 terminated, 7 active not recruiting. 45 Phase 2, 26 Phase 1, 5 Phase 3, 3 Phase 4, 1 Early Phase 1.
Follow Eribulin Mesylate: new trials by email Literature Review of Eribulin Mesylate trials Research Report on Eribulin Mesylate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Withdrawn | National Cancer Institute (NCI) | 2025-08-04 | 2025-07-03 | |
| Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical Trial Eribulin, Sintilimab - Metastatic Breast Cancer | Phase 2 | Unknown | Zhejiang Cancer Hospital | 81 | 2024-03-08 | 2024-03-13 |
| EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma Eribulin Mesylate, Pembrolizumab - Ovarian Carcinosarcoma, Uterine Carcinosarcoma | Phase 2 | Completed | Australia New Zealand Gynaecological Oncology Group | 13 | 2023-05-22 | 2026-08-06 |
| A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02) Dato-DXd, Paclitaxel, Nab-paclitaxel - Breast Cancer | Phase 3 | Active not recruiting | AstraZeneca | 644 | 2022-05-16 | 2026-05-15 |
| Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer Eribulin Mesylate, Grapiprant - Breast Inflammatory Carcinoma, Recurrent Breast Inflammatory Carcinoma | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 6 | 2021-12-21 | 2025-06-13 |
| A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01) Dato-DXd, Capecitabine, Gemcitabine - Breast Cancer | Phase 3 | Active not recruiting | AstraZeneca | 732 | 2021-10-18 | 2026-08-24 |
| Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer Biospecimen Collection, Bone Scan, Computed Tomography - Metastatic Bladder Urothelial Carcinoma, Metastatic Urothelial Carcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 131 | 2021-06-28 | 2026-11-12 |
| Maintenance Treatment With Eribulin Mesylate Versus Observation in Triple Negative Breast Cancer Patients Eribulin Mesylate - Triple Negative Breast Cancer | Phase 2 | Unknown | The First Affiliated Hospital with Nanjing Medical University | 100 | 2021-06-01 | 2020-08-11 |
| Eribulin Combined With Anlotinib in Metastatic HER2 Negative Breast Cancer Eribulin Mesylate, Anlotinib hydrochloride - HER2-negative Breast Cancer | Phase 2 | Unknown | The First Affiliated Hospital with Nanjing Medical University | 40 | 2021-03-01 | 2021-05-21 |
| Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 24 | 2021-03-01 | 2026-11-18 |
| Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer Eribulin Mesylate, Anlotinib - Metastatic Breast Cancer | Phase 2 | Completed | Hunan Cancer Hospital | 80 | 2020-10-09 | 2022-11-23 |
| Eribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent or Metastatic Triple-negative Breast Cancer Eribulin Mesylate, Lobaplatin - Triple Negative Breast Cancer | Phase 2 | Unknown | Chinese Academy of Medical Sciences | 40 | 2020-06-01 | 2022-09-19 |
| A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBC Camrelizumab, Apatinib, Eribulin - Breast Cancer | Phase 2 | Unknown | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 46 | 2020-03-25 | 2023-04-12 |
| Eribulin With or Without Trastuzumab-biosimilar in Patients With HER2-overexpressed Recurrent or Stage IV Breast Cancer Eribulin Mesylate + Samfenet (Trastruzumab-biosimilar), Eribulin Mesylate - Advanced Breast Cancer | Phase 2 | Recruiting | Seoul National University Hospital | 180 | 2020-02-18 | 2025-11-20 |
| Breast Cancer Treatment Based on Organ-like Culture Trastuzumab, Doxorubicin Hydrochloride, Epirubicin hydrochloride - Breast Cancer Organoids | Unknown | Xijing Hospital | 300 | 2019-01-02 | 2019-04-24 | |
| Second Line ERIbulin Followed by CApecitabine or the Reverse Sequence in HER2-negative Metastatic Breast Cancer Patients Eribulin Mesylate, Capecitabine - Metastatic Breast Cancer | Phase 2 | Unknown | Consorzio Oncotech | 122 | 2018-07-30 | 2023-04-27 |
| Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer Atezolizumab, Biopsy Procedure, Biospecimen Collection - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 72 | 2018-07-20 | 2026-11-18 |
| A Study Combining Eribulin Mesylate With Avelumab in Cisplatin Ineligible Metastatic Urothelial Cell Cancer Patients Eribulin Mesylate, Avelumab - Metastatic Urothelial Cell Cancer | Phase 1 | Terminated | Monika Joshi, MD | 6 | 2018-06-12 | 2022-07-01 |
| M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer Bintrafusp Alfa, Eribulin Mesylate - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma | Phase 1 | Terminated | M.D. Anderson Cancer Center | 38 | 2018-05-30 | 2022-10-31 |
| Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Participants With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS) Eribulin mesylate - Relapsed/Refractory Rhabdomyosarcoma, Non-rhabdomyosarcoma Soft Tissue Sarcoma | Phase 2 | Completed | Eisai Inc. | 23 | 2018-04-17 | 2022-10-05 |
Showing 20 of 77. Sign in to see all of them.
Breast Neoplasms (37) · Neoplasms (8) · Triple Negative Breast Neoplasms (8) · Neoplasm Metastasis (5) · Sarcoma (3) · Urinary Bladder Neoplasms (3) · Brain Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (2) · Carcinoma, Transitional Cell (2) · Lymphoma (2) · Ureteral Neoplasms (2) · Urethral Neoplasms (2) · Breast Neoplasms, Male (1) · Carcinoma, Ovarian Epithelial (1) · Drug-Related Side Effects and Adverse Reactions (1)
Eisai Inc. (17) · National Cancer Institute (NCI) (15) · Eisai Co., Ltd. (4) · Eisai Limited (4) · AstraZeneca (2) · City of Hope Medical Center (2) · Dana-Farber Cancer Institute (2) · Eisai Korea Inc. (2) · M.D. Anderson Cancer Center (2) · The First Affiliated Hospital with Nanjing Medical University (2) · University of Washington (2) · Academic and Community Cancer Research United (1) · Australia New Zealand Gynaecological Oncology Group (1) · Case Comprehensive Cancer Center (1) · Chang Gung Memorial Hospital (1)
United States (47) · Canada (10) · China (9) · United Kingdom (7) · Italy (6) · Japan (6) · France (5) · Germany (5) · South Korea (5) · Spain (5) · Taiwan (5) · Belgium (4) · Netherlands (4) · Argentina (3) · Brazil (3)
Sam Misir (3) · Sarmad Sadeghi (2) · Amanda Linz, MD (1) · Anishka A D'Souza (1) · Barbara Gitlitz (1) · Clare Scott, AM MB BS PhD (1) · David I Quinn (1) · Dr. Claudio Savulsky (1) · Giovanna Damia, PHD (1) · Hannah Linden (1) · Harish Dave (1) · Heather Han, M.D. (1) · Hiroshi Obaishi (1) · Jana Portnow, MD (1)
PMID 20299316, PMID 21935916, PMID 24699910, PMID 25605862, PMID 26006067, PMID 26126970, PMID 26554651, PMID 26567010, PMID 27391598, PMID 27398025, PMID 28660549, PMID 30783204, PMID 31365116, PMID 31390274, PMID 31703728, PMID 32827353, PMID 32880602, PMID 33741296, PMID 34302589, PMID 34548479, PMID 35546669, PMID 35641481, PMID 36307826, PMID 37387213, PMID 37526149, PMID 39265124, PMID 39422741, PMID 42501677
2009 (3), U01CA062505 (3), 2023 (2), N01CM00038 (2), N01CM62201 (2), N01CM62209 (2), P30CA033572 (2), UM1CA186717 (2), 2015 (1), N01CM00032 (1), N01CM00071 (1), N01CM17107 (1), N01CM62203 (1), N01CM62204 (1), N01CM62206 (1)